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After a single inhalation from an inhaler by six normal volunteers the mean concentration of fluorocarbon-12 in alveolar gas had reached 5-5 ,ug/ml, giving a mean apparent volume of distribution of 7 94 litres compared with the mean predicted total lung capacity of 6-61 litres. These results suggest that most of the fluorocarbon expelled from the inhaler entered the alveolar gas. The mean alveolar concentration of F-l1 was 2-7 Vg/ml and the mean apparent volume of distribution was 12-46 litres. The higher volume of distribution with the less volatile F-1l probably reflects the amount dissolved in lung tissue and pulmonary capillary blood. Similar results were obtained in two patients with obstructive airways disease.
One volunteer took an inhalation on every breath up to two minutes and reached an alveolar concentration of F-li of 29'6 t±g/ml and of F-12 of 66-9 ,ug/ml. The concentration of F-1I required to sensitize the dog heart to arrhythmias was 68 ,ug/ml. Thus there should be no hazards from the amount entering alveolar gas in normal use after a single inhalation. Inhalation upon every breath over a period raises the alveolar concentration to one approaching that which, in the dog, might be hazardous.
The increase in deaths from asthma in Britain between 1960 and 1967, although never fully explained, is generally accepted to have been linked with the use of pressurized aerosols for administration of bronchodilator drugs (Speizer, Doll, and Heaf, 1968; Speizer, Doll, Heaf, and Strang, 1968) . Most of these aerosols contain fluorocarbons-11 and -12 (F-I 1, CCl3F; F-12, CC12F2) as propellants. Interest in a possible role for these compounds in causing sudden death was aroused by reports of deaths among 'solvent sniffers' in the United States of America (Bass, 1970) arrhythmias provoked by intravenous injection of adrenaline (Clark and Tinston, 1972a, b) . The present investigation was undertaken to measure alveolar gas concentrations of these substances after use of an inhaler and to compare the concentrations with those known to sensitize the animal hearts to arrhythmias. As wide individual differences in concentration were found, including some individuals who had almost nq fluorocarbon in their alveolar gas, the study was extended to include a breath-actuated inhaler ('Autohaler'; D'Arcy and Kirk, 1971) which avoids the difficulty of mistiming the valve actuation.
Mass spectrometry was used in the measurement of F-i1 and F-12 on successive breaths up to two minutes after inhalation from the aer9sols.
The mass spectra differed significantly only in the higher mass fragments (F-12, m/e 85; F-1l, m/e 101). A simple two-stage continuous inlet system for breath analysis (Muysers and Smidt, 1972) Mixtures of F-11 and F-12 of approximate concentrations in the range 1-60 jig/ml in air saturated with water vapour at room temperature were prepared in heat-sealable polyester bags. Samples (1i0 ml) were removed in gas-tight syringes through silicone rubber plugs and the F-l1 and F-12 concentrations were measured by gas chromatography (flame ionization detection) using a 6 ftx* in o.d. column of 15 % dihexylethyl sebacate at 800 in a Pye 104 chromatograph. Mass spectrometer response to F-I 1 and F-12 was determined with these standards.
Sampling times were limited to less than five seconds attachment to the inlet capillary; no relative enrichment of either component or significant loss by dissolution in the material of the bag was observed during a day's calibration. The precision of measurement of F-ll was ±12% (SD) at 2 ,ug/ml and of F-12±l0% (SD) at 4 ,ug/ml).
MEASUREMENT OF LUNG CONCENTRATIONS The aerosol inhaler used was Th 1165a placebo (Boehringer) releasing 50 ,ul of liquified fluorocarbons of composition 28-7 mg F-il and 41i0 mg F-12 per actuation.
Six healthy adult volunteers and two patients with obstructive airway disease were asked to make a maximal inspiration from the resting expiratory level while actuating this inhaler, to hold their breath for five seconds, and then to breath at a normal rate through the mouthpiece. F-11 and F-12 were recorded on alternate expired breaths for 30 to 120 seconds.
In three further studies, a volunteer inhaled one puff from the Th 1165a placebo on successive breaths for 30, 60, and 120 seconds (6, 12, and 24 puffs respectively). In these acute studies the electrocardiogram was recorded from precordial electrodes and charted on a pen recorder (Devices M4).
In The first was a rapid and progressive rise to a plateau after a short initial lag while the dead space was cleared (Fig. la) . This is the pattern predicted from inserting a pulse of fluorocarbon into the inhaled gas during the early part of inspiration so that it is flushed into the alveolar gas by air inhaled in late inspiration. Thus the dead-space gas is free of fluorocarbon and there is a delay while it is cleared before the alveolar gas-containing fluorocarbon appears at the sampling tube.
The second pattern consisted of a high spike of fluorocarbon concentration immediately after the start of expiration followed by much lower concentrations later in expiration (Fig. lb) . This Alveolar gas concentrations of fluorocarbons-li a'nd -12 in man after use of pressurized aerosols 97 There are probably two main reasons for the difference between the predicted total lung capacity and the volume of distribution of the fluorocarbons. The first is loss of fluorocarbon because the gas jet emerging from the inhaler did not all enter the mouth. The results with F-12, where the volume of distribution was 120% of total lung capacity, suggest that this was not an important source of loss. The higher distribution volumes with F-il probably arise because of the higher boiling point and greater blood solubility of this substance than F-12 respectively of those which had to be maintained for five minutes in dogs to sensitize their -entricular myocardium to arrhythmias provoked by adrenaline. Furthermore, the peak concentration in alveolar gas was of very brief duration after the use of the inhaler. We have shown in other studies with labelled F-11 in rats that its distribution into and out of tissues depends upon their blood flow and the blood/ tissue partition coefficient . Unless there is a very great difference in the concentrations required to sensitize the human and dog hearts it appears that there could be no hazard from a single inhalation at least in respect of the fluorocarbon propellants.
In the single study in which multiple inhalations were given, the alveolar gas concentration approached the values that sensitize the dog heart to arrhythmias, although the electrocardiogram of the volunteer was normal throughout. If the effect of different fluorocarbons is additive, as is probable because of their similar structure and mode of action, such a combined concentration might be hazardous. Thus it would be unwise for a patient to actuate the inhaler upon every breath over a period, and the instructions for use now warn against overdosage. A few normal breaths between doses would prevent accumulation of fluorocarbon in the lung. 
